What You Should Know
- Almanac Health has raised $10M in a seed round led by F-Prime, with participation from General Catalyst and Lightspeed Venture Partners, bringing total funding to nearly $12M.
- The platform was founded by Cyril Zakka, MD, a physician-researcher at Stanford who developed the first retrieval-augmented generation (RAG) system for clinical medicine.
- Unlike many “black box” solutions, Almanac is grounded in peer-reviewed evidence and is currently undergoing rigorous clinical validation in academic medical centers.
- The software integrates directly into existing Electronic Health Record (EHR) systems and is designed to operate free from pharmaceutical advertising.
- Funding will be used to grow a cross-functional team in clinical medicine, AI research, and health systems infrastructure while advancing privacy-focused R&D.
The clinical AI landscape is crowded with tools promising to revolutionize medicine, yet many fail to meet the rigorous evidence standards required by frontline physicians. Almanac Health, a unified clinical AI platform, has launched with a $10M seed round to address this specific trust deficit. Founded by Cyril Zakka, MD, the company aims to move beyond simple automation to provide specialist-grade knowledge that is grounded in peer-reviewed research and governed by strict institutional controls.
The platform’s technical foundation is rooted in retrieval-augmented generation (RAG), an approach now widely adopted across the industry but pioneered by Dr. Zakka during his tenure at Stanford. By anchoring generative AI in trusted medical knowledge rather than relying on the broad, unverified data sets used by generalist models, Almanac Health ensures that its clinical decision support is both reliable and safe. This methodology was established in one of NEJM AI’s most-cited papers, providing the company with an early lead in scientific credibility.
Scaling Frontier Intelligence into Daily Clinical Workflows
The ultimate goal of Almanac Health is to translate high-level frontier intelligence into the mundane but critical decisions made by clinicians every day. The platform is designed to work seamlessly within existing EHR systems, ensuring that specialist-grade intelligence is available at the point of care without disrupting established workflows. This “physician-centric” approach is a direct response to the burnout and friction caused by poorly integrated healthcare technologies.
With the new capital, Almanac plans to grow a team that sits at the intersection of technical depth and clinical expertise. The company is prioritizing R&D that focuses on privacy and reliability, ensuring that institutional data remains secure while the AI delivers actionable insights. According to the company’s investors, this represents the “next generation” of healthcare infrastructure—one where incentives are aligned with patient outcomes rather than pharmaceutical advertising or administrative metrics.
Institutional Governance and the Path to Trust
Trust is the central theme of Almanac’s market entry. The platform is not being deployed as a finished product but is instead undergoing continuous validation in academic medical center settings. This commitment to rigorous evaluation before full-scale deployment is intended to satisfy the high bar set by health system leaders who require accountability and alignment. By operating under institutional controls, Almanac allows hospitals to maintain authority over how AI-generated intelligence is used within their walls.
The involvement of high-profile venture firms like F-Prime and General Catalyst underscores the market’s appetite for “Safe AI.” These investors see Almanac as a vehicle for “Health Assurance”—a model where technology provides the alignment and accountability necessary for true systemic transformation. As the company begins hiring across engineering and clinical development, its focus remains steadfast on building a standard for clinical AI that is as rigorous as the peer-reviewed science it draws upon.
Why This Matters
Almanac Health is entering the market at a critical pivot point for healthcare AI. The industry has moved past the initial “wow factor” of large language models and is now demanding the one thing most models lack: clinical evidence. By leveraging Dr. Zakka’s foundational work in RAG, Almanac isn’t just another AI startup; it is the commercialization of the very methodology that made clinical AI viable in the first place.
